The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Metformin may reduce knee pain in overweight patients with osteoarthritis, offering a low-cost alternative to early knee ...

Type 2 diabetes is a long-term condition where the body struggles to manage sugar levels in the blood. Normally, doctors ...

One primary reason people seek a blood sugar supplement that works is to maintain stable glucose levels throughout the day.

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But ...

A very low-carb diet significantly improved the pancreas’s ability to produce insulin in people with mild Type 2 diabetes ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

Successfully treating type 2 diabetes may involve focusing on brain neurons, rather than simply concentrating on obesity or insulin resistance, according to a study published today in the Journal of ...

while those with type 2 diabetes may need medications such as metformin, SGLT2 inhibitors, or GLP-1 receptor agonists, along with lifestyle changes. Regular monitoring of blood sugar levels is a ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.